BioNexus (BGLC) Director Low Jook Yuen Receives 16,129-Share Award

What Happened

• Low Jook Yuen, a director of BioNexus Gene Lab Corp. (BGLC), was granted and immediately acquired (award) 16,129 shares of common stock on August 13, 2026. The Form 4 lists the transaction as an award/acquisition (code A) and shows no cash paid by the insider.
• The award is fully vested and was valued for plan purposes at $1.55 per share (Nasdaq closing price on August 12, 2026), giving a plan-value of approximately $24,999.95 (~$25,000).

Key Details

• Transaction date: August 13, 2026 (Form 4 filed August 14, 2026 — appears timely).
• Price reported on Form 4: N/A for award; plan valuation: $1.55/share (per footnote).
• Shares granted/acquired: 16,129 shares (fully vested Other Stock-Based Award under the 2025 Equity Incentive Plan).
• Consideration: No cash paid; granted for completed services.
• Shares owned after the transaction: Not specified in the filing.
• Footnote: F1 confirms the award was granted under the 2025 Equity Incentive Plan, fully vested, granted for services, and valued at $1.55/share for plan purposes.

Context

• This was a compensation award (grant), not an open-market purchase or sale. Awards compensate service and do not necessarily signal an insider's view on near-term stock performance.
• Because the award is fully vested, the shares are owned outright by the director and could be sold later; no immediate sale was reported in this filing.